Qualcomm Stock Jumps on Amazon AI Chip Deal 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
Asian Currencies Steady as Yen Holds Firm, Oil Tops $100 
Zara Owner Inditex Sales Rise 9% in August 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities 
White House Weighs Refined Copper Tariffs as Cost Concerns Grow 
Boeing, SPEEA Reach Tentative Four-Year Labor Deal 
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Fitch Eyes Japan Budget for Fiscal Discipline 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Kioxia Rules Out SK Hynix Manufacturing Partnership 
Add as a preferred source on Google
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
